Sol-Gel Technologies (SLGL) Current Leases (2019 - 2026)
Sol-Gel Technologies (SLGL) posted quarterly Current Leases of $485000.0 for Q1 2026, up 12.01% year-over-year from $433000.0 in Q1 2025, and down 2.02% quarter-over-quarter from $495000.0 in Q4 2025.
Powered by 
Analysis
Sol-Gel Technologies (SLGL) Current Leases (2019 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Current Leases for 8 consecutive years, with $485000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Leases rose 12.01% year-over-year to $485000.0; the TTM figure through Mar 2026 stood at $485000.0 (up 12.01% YoY), while the FY2025 annual figure was $495000.0, up 15.12% from the prior year.
- Current Leases eased to $485000.0 in Q1 2026 per SLGL's latest filing, from $495000.0 in the prior quarter.
- Across five years, Current Leases topped out at $766000.0 in Q1 2022 and bottomed at $376000.0 in Q2 2024.
- Historically, Current Leases has averaged $513352.9 across 5 years, with a median of $482000.0 in 2025.
- Annual changes were most pronounced in 2023 — Current Leases slumped 38.23% — and 2025, when it rose 28.19%.
- Sol-Gel Technologies' Current Leases stood at $718000.0 in 2022, then sank by 37.74% to $447000.0 in 2023, then declined by 3.8% to $430000.0 in 2024, then increased by 15.12% to $495000.0 in 2025, then fell by 2.02% to $485000.0 in 2026.
- Business Quant data shows SLGL's Current Leases at $485000.0 in Q1 2026, $495000.0 in Q4 2025, and $491000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 11.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 16.75 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 21.95 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 45.93 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Sol-Gel Technologies | 194.01 Mn | 146.08 Mn | - | 519,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 519,000.00 |
| Mar 31, 2026 | 485,000.00 |
| Dec 31, 2025 | 495,000.00 |
| Sep 30, 2025 | 491,000.00 |
| Jun 30, 2025 | 482,000.00 |
| Mar 31, 2025 | 433,000.00 |
| Dec 31, 2024 | 430,000.00 |
| Sep 30, 2024 | 384,000.00 |
| Jun 30, 2024 | 376,000.00 |
| Mar 31, 2024 | 386,000.00 |
| Dec 31, 2023 | 1.59 Mn |
| Sep 30, 2023 | 467,000.00 |
| Jun 30, 2023 | 433,000.00 |
| Mar 31, 2023 | 544,000.00 |
| Dec 31, 2022 | 88,000.00 |
| Sep 30, 2022 | 689,000.00 |
| Jun 30, 2022 | 701,000.00 |
| Mar 31, 2022 | 766,000.00 |
| Dec 31, 2021 | 253,000.00 |
| Sep 30, 2021 | 652,000.00 |